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Abstract
Background: Worldwide there is a need to develop simple effective predictors that can distinguish whether a
patient will progress from dengue fever (DF) to life threatening dengue hemorrhagic (DHF) or dengue shock
syndrome (DSS). We explored whether proteinuria could be used as such a marker.
Methods: We included patients admitted to hospital with suspected dengue fever. Starting at enrollment until
discharge, each patient’s daily spot urine protein creatinine ratio (UPCR) was measured. We classified those with
confirmed dengue infection as DF or DHF (including DSS) based on WHO criteria. Peak and day of onset of
proteinuria was compared between both groups.
Results: Compared to those with DF, patients with DHF had significantly higher median peak proteinuria levels
(0.56 versus 0.08 g/day; p < 0.001). For patients with DHF, the median day of onset of proteinuria was at 6 days of
defervescence, with a range of -2 to +3 days after defervescence. There were three patients with DF who did not
have proteinuria during their illness; the five remaining patients with DF had a median day of onset of proteinuria
of was of 6 days of defervescence with a range of 0 to +28 days.
Conclusions: Peak UPCR could potentially predict DHF in patients with dengue requiring close monitoring and
treatment.
Background
Dengue is the most prevalent mosquito- borne viral dis-
ease in South East Asia [1]. It is caused by four dengue
virus strains from the genus Flavivirus and transmitted
by the Aedes aegypti mosquito. The risk of severe disease
and death underscores the importance of early detection
of dengue fever (DF) and monitoring for signs of progres-
sion to severe disease. Currently, there are no simple
clinical and laboratory markers that can predict whether
a patient with DF will develop life threatening dengue
hemorrhagic fever (DHF) or dengue shock syndrome
(DSS) [2]. There is a need to develop a simple effective
predictor that can identify patients at risk of severe
disease. Ideally, the test should be cheap, fast, highly sen-
sitive and specific.
Previous studies have documented proteinuria during
t h ec o u r s ed e n g u ef e v e r .I n1 9 9 5 ,G a r c i ae ta lo b s e r v e d
proteinuria in 22% of dengue fever patients, 38% of
whom had it within the first 4 days of the onset of consti-
tutional symptoms [3]. But the authors did not compare
the occurrence of proteinuria by severity of disease. In
2004, Wills et al demonstrated among children with DSS
markedly reduced plasma concentrations of different-
sized proteins with a corresponding increase in fractional
urinary clearances of the same proteins. They suggested
that a simple test of urine protein excretion may become
a useful predictor for the subsequent development of
DHF and DSS [4]. In 2010, Lumpaopong et al found
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of those with DHF (p = 0.072) [5].
We previously reported two patients with dengue
hemorrhagic fever, who developed self-limiting gross
nephrotic range proteinuria without evidence of renal
damage such as an increase in serum creatinine, hematuria
and urinary casts [6]. The objective of this study is to
assess whether proteinuria could be used to indicate
which patients with dengue fever would progress to DHF
or DSS.
Methods
Study site and population
The study was conducted at the Singapore General Hospi-
tal (SGH). SGH is the country’s oldest and largest tertiary
hospital and national referral center with 1521 acute-care
beds. Admission criteria for suspected dengue is presence
of one or more of the following: significant bleeding,
severe vomiting or diarrhea that requires intravenous infu-
sion, blood pressure < 90/60 mm Hg and/or pulse rate >
100 beats/minute, severe abdominal pain, dehydration
with electrolyte abnormalities and/or postural hypoten-
sion, are elderly with medical co-morbidities and are
unwell, hematocrit > 50% or platelet count < 80,000 cells/
mm
3[7]. Adult patients are admitted and managed accord-
ing to WHO guidelines [8]. The following working day,
the patients are transferred to the Department of Family
Medicine and Continuing Care, where they were prospec-
tively enrolled into the study. Exclusion criteria were,
negative confirmatory test for dengue, failure to follow
study protocol and preexisting renal disease.
Clinical and laboratory procedures
Dengue infection was confirmed by the detection of IgM
antibodies using the Dengue Fever Virus IgM capture
ELISA kit (Focus Technologies™, CA, USA) [9]. In addi-
tion, we used real time one step reverse transcriptase PCR
(RT-PCR) following standard procedures to confirm sus-
pected cases of dengue fever [10]. False positive cases due
to cross-reactivity using the IgM blots and RT-PCR are
minimal because Japanese Encephalitis incidence is very
low in Singapore, and Yellow Fever has never been
detected in this region [11]
Patients’ vital signs were measured every one to two
hours. Postural blood pressure was taken three times
daily. Patients with a postural drop in blood pressure of
at least 20 mmHg in systolic and 10 mmHg in diastolic
pressure readings from the lying to the standing positions
were aggressively hydrated based on intravenous admin-
istration of sodium chloride 0.9% given initially at a maxi-
mum of 10-20 ml/kg/hour. If clinical improvement is
observed, successful reduction of intravenous fluid 10 to
6 and 6 to 3 ml/kg/hour is made till clinical improvement
is sustained i.e., hematocrit falls, pulse rate and blood
pressure stable, and urine output rises. Patients with pos-
tural hypotension were examined twice daily especially
for evidence of petechiae, purpura, ecchymoses, bleeding
from mucosa, gastrointestinal tract or other sites.
Daily platelet counts and hematocrit were measured.
Chest x-ray and/or ultrasound of the abdomen were
conducted to verify pleural effusion, ascites or other
signs of plasma leakage as clinically indicated. Electro-
lyte levels, liver function and renal function tests were
carried out as clinically indicated.
Urine protein creatinine ratio
Starting at enrollment until discharge, each patient’s daily
spot urine protein creatinine ratio (UPCR) was measured.
As the normal physiologic amount of protein excreted is
less than 0.20 gm/mg per day, we consider insignificant
proteinuria as 0.06 to 0.19 gm/mg and significant protei-
nuria as 0.20 gm/mg or greater [12]. Patients who contin-
ued to have proteinuria at discharge were followed-up to
confirm normalization of his or her UPCR.
Definitions and data analysis
We used WHO clinical criteria to distinguish DHF from
DF by the presence of hemorrhagic manifestations,
thrombocytopenia and hemo-concentration [8]. Hemo-
concentration is defined as an increase of the hematocrit
of 20% or more; or evidence of plasma leakage such as
pleural effusion, edema and ascites. Thrombocytopenia
is defined as platelet count less than 100 × 10
9/L. DHF
cases with circulatory failure (evidenced by a rapid and
weak pulse, narrowing of pulse pressure to < 20 mm Hg
or hypotension) or profound shock with undetectable
blood pressure and pulse were classified as DSS.
The onset of the illness was defined as the first day of
fever. The day of defervescence (DDf) was defined as
the number of days from the onset till the remission of
fever. For the analysis, onset of proteinuria, the day of
peak UPCR, and day of lowest platelet count, was
rescaled from the DDf, considering DDf as day 0.
Statistical analysis was performed using SPSS software
version 17 (IBM Corporation, Somers, NY, USA). Median,
together with range, was used to describe continuous vari-
ables (UPCR, platelet count, day of peak UPCR, and day of
onset of proteinuria, and hematocrit on the day of peak
UPCR. The data were compared between the groups with
DF and DHF (including DSS) using Fisher t-test and the
Mann-Whitney’s U-test, respectively. Categorical data
were presented as frequency, with percentages shown in
parentheses and were analyzed using Chi-square test.
Statistical significance was taken as p-value < 0.05.
Ethics
Ethical clearance was obtained from the SingHealth
Centralized Institutional Review Board. (CIRB reference
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IRB as the collection of urine samples is non-invasive
and did not constitute harm to the patient. Data were
anonymized at entry and analysis. The patients were
informed that the urinalysis was used to quantify the
amount of protein during their illness.
Results
From March 2009 to March 2011, 46 patients admitted
with suspected dengue infection were admitted (Figure 1).
Six patients were negative for dengue serology and PCR,
four patients did not follow the study protocol as described
and three patients had preexisting renal disease. These 13
(17%) patients were excluded from the study. Among the
33 (83%) patients studied, eight cases (24%) were classified
as uncomplicated dengue fever (DF) and 25 (76%) cases as
DHF, including two cases with DSS (Figure 1).
Demographics of patients with DF and DHF are shown
in Table 1. Patients with DF were significantly younger
compared to those with DHF (34 ± 12 vs. 43 ± 11 years,
p = 0.05). There was no difference in the level of hemato-
crit between these two group of patients as these patients
were aggressively hydrated during admission, hence the
hematocrit levels falls rather than rises during admission
[7].
Table 2 shows the proteinuria and platelet parameters of
patients with DF and DHF. Compared to those with DF,
patients with DHF had significantly higher median peak
UPCR levels (0.56 gm/mg vs. 0.08 gm/mg; p < 0.001). 96%
(24 of 25) of patients with DHF developed significant
UPCR, compared to none with DF developing significant
proteinuria (3 out of 8 had non detected UPCR below 0.06
g/dl) (c
2 = 28.2, p = 0.0005). For patients with DHF, the
day of proteinuria-onset in DHF group was closer than
that of DF group (I, -2 to +3 day vs. 1, 0 to +9 day in DF,
p = 0.02). 19 (76%) of 25 patients with proteinuria that
were followed up, had normalization of UPCR. The rest
was lost to follow up.
Discussion
In our series, patients with uncomplicated DF did not
develop significant proteinuria, while 96% of patients with
impending dengue hemorrhagic fever and dengue shock
syndrome developed that. In addition, they developed
maximum proteinuria near the day of defervescence. This
corresponded to the lowest platelet count as well that
developed around the same period as the constitutional
symptom i.e. fever disappeared [13]. We found a statisti-
cally significant association of higher degree of thrombocy-
topenia with significant proteinuria (Table 2). The degree
of thrombocytopenia also corresponds to the severity of
other types of hemorrhagic viral fever [14]. However we
noted that proteinuria is self limiting and resolves on reso-
lution of the illness.
Epidemiologically dengue fever is a frequently occurring
illness in children and adult of the developing nations in
Asia, Africa and South America with an increasing mor-
bidity and mortality because of hemorrhagic complication
or dengue shock syndrome [15-17]. Complicated dengue
carries a higher mortality and morbidity rate in both pedia-
tric and adult population. Early prediction and detection of
dengue complication could enable physicians manage the
complicated dengue cases with a better strategy for pre-
venting mortality and morbidity. In a recent retrospective
study, Lima et al, showed that detection of NS1 antigen of
dengue virus (DENV) in tissues of dengue fatal cases had a
strong positive association with confirmation of previously
fatal cases of dengue fever. Even though, this DENV NS1
capture assay was studied as a test for a rapid and valuable
postmortem dengue diagnostic test, they postulated that,
with an increasing number of DHF and associated fatality,
the availability of this new approach would be useful for
the disease surveillance [18]. Although this is an approach
for early diagnosis of DHF by antigen assay, it may not be
practicable in clinical practice as it is a tissue diagnosis
based on postmortem tissue analysis of fatal cases.
Association of proteinuria in dengue has been known to
investigators for sometime.B u t ,t h e yc o u l dn o tf i n da n y
difference in proteinuria between DF and DHF [5]. Unlike
our study, these studies did not differentiate between sig-
nificant and non-significant proteinuria. We could not
identify in literature any study measuring daily UPCR for
detecting peak proteinuria, as one sample of spot UPCR
may not be representative of peak proteinuria for the
representative case. These could explain the observation of
lack of difference in proteinuria between DF and DHF in
those studies.
The importance of proteinuria resulting from dengue
induced secondary glomerulonephritis is elucidated in lit-
erature by various authors [19]. Renal biopsy in DHF, even
showed the presence of IgA nephropathy that was transi-
ent in nature, showing the possibility of immune-complex
disease in dengue fever because of DENV associated anti-
gen-antibody-complex deposition in renal glomerular tis-
s u e[ 2 0 ] .I d e n t i f i c a t i o no fs o l u b l ei m m u n ec o m p l e xi n
DHF specific for dengue virus in serum reiterates this
issue [21]. Antibodies to DENV were known to be asso-
ciated with DHF in earlier studies as back as 1969 [22]. In
-vitro studies with normal human B-lymphocytes demon-
strated the detection of immune complex with preformed
dengue antigen. This indicates that dengue immune com-
plex might deposit in vascular and glomerular tissue lead-
ing to vasculitis of DHF and glomerulnephritis leading to
proteinuria [23]. The degree of proteinuria (peak UPCR as
studied in our series) might indicate the severity of dengue
infection. The significant peak proteinuria could be a man-
ifestation of an autoimmune pathogenetic mechanism that
the virus triggers on the lympho-reticular system, resulting
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associated with DHF [6]. Thus, peak UPCR could have an
impact on predicting evolution of DHF. However, the glo-
merulonephritis itself resolves when the patient recovers
from the illness.
Limitation of our study was the absence of renal
biopsy to document and confirm glomerulonephritis in
cases of significant UPCR as it was felt not necessary
because of the self limiting nature of proteinuria. The
other limitation was the lag period between admission
of the case and initiation of collection of spot urine for
UPCR, as urine was collected only after including the
case in the study protocol after meeting the inclusion
criteria. The study protocol would be initiated after the
case had been transferred to study team from the admit-
ting team. Since we measured daily UPCR for detecting
the peak, this limitation mi g h tn o th a v ea ni m p a c to n
the final outcome. The onset of proteinuria could have
been earlier in fact. In spite of these limitations we
strongly feel that the peak UPCR in dengue should be
Figure 1: Flow of participants 
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46 hospitalized patients with suspected dengue from March 2009 to March 
2011 
40 (86%) Patients:   -  29 with positive dengue IgM 
-  4 with confirmatory dengue PCR 
-  7 with positive IgM and PCR 
33 (83%) patients included in the analysis 
Excluded 6 patients: As dengue PCR and 
dengue serology were negative. 

Excluded 7 (17%) patients: 
4 did not follow predefined protocol 
3 with pre-existing renal disease 
8 (24%) patients with dengue fever  25 (76%) patients with dengue hemorrhagic
fever, 2 (8%) of whom had dengue shock
syndrome)
Figure 1 Flow of participants in the study. Cases are derived from the cases enrolled in the Department of Family Medicine and Continuing
Care, Singapore General Hospital.
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ter suspected cases of dengue as the onset of proteinuria
and subsequent demonstration of peak UPCR could
have a major implication in identification of incipient
DHF and stratification of management strategy for such
cases. The primary physician in the community has an
advantage of seeing the patients earlier. They can
administer the relevant tests including the UPCR more
quickly. This may better assist the physician to stratify
the severity of the illness earlier on. A similar analogy
would be the diagnosis of preeclampsia/eclampsia,
where the onset of new onset proteinuria from a patient
without preexisting renal disease is highly significant of
impending disease [24].
Further studies to define a commercially available urine
dipstick equitable to the UPCR for detecting urinary pro-
tein in a patient with dengue with good sensitivity and
specificity would reduce the difficulty of UPCR estimation.
This test with a threshold value of 0.20 gm/mg could be
used as an early warning system for predicting dengue
complications. Further studies with large series of patient
at multi-center set-up and improved protocol of collection
of urine at primary care levels, are required to validate the
important positive finding of our small series. Protocol
could include use of use of urine dip-stick and UPCR
together to validate more convenient urine dip-stick over
the complicated and laboratory dependent UPCR.
Conclusion
We conclude that the onset and the peak of proteinuria
using the UPCR have a significant association with sub-
sequent development of DHF. Therefore, the daily
UPCR could be a useful simple adjunct for physicians in
the community hospital for early determination of den-
gue complications.
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Table 1 Characteristics of patients with dengue fever (DF) and dengue hemorrhagic fever (DHF), including dengue
shock syndrome (DSS)
Dengue
(N = 8)
DHF/DSS
(N = 25)
P value
Mean (± SD) range in years 34 (12) 43 (11) 0.058
Median (range) number of days of illness prior to admission 6(3,9) 5(2,7) 0.190
Median (range) DDF
1 in days 6(0,10) 6(3,7) 0.789
Median (range) number of total days of illness 9(6,10) 9(7,12) 0.220
Median (range) platelet count in 10
9/L at the day of peak proteinuria 70 (43,118) 41(14,149) 0.019
Median (range) of hematocrit in % during the peak of proteinuria 40.6 (38,48) 41.2 (32,48) 0.914
1DDF: day of defervescence from the onset of the illness
2The hematocrit is not significantly different due to aggressive intravenous hydration when the patients were admitted. Hydration affects the hematocrit values.
The degree of intravenous hydration depends whether the patient has DF or DHF/DSS.
Table 2 Proteinuria and platelet parameters of patients with dengue fever (DF) and dengue hemorrhagic fever (DHF),
including dengue shock syndrome (DSS)
DF
(N = 8)
DHF/DSS
(N = 25)
P value
Median (range) peak proteinuria in gm/mg 0.08 (0.06,0.15) 0.56 (0.13,6.08) < 0.001
Median (range) day of onset of proteinuria
1 6 (0, +28) 1 (-2, +3) 0.020
Median (range) day of peak proteinuria
2 6 (0, +28) 1 (0, +3) 0.107
Median (range) nadir platelet count
2 in 10
9/L 74 (43,97) 33(11,103) < 0.001
Median (range) day of nadir platelet count
3 0 (-2,+2) 1(-1,+3) 0.204
Median (range) platelet count in 109/L at the
day of peak proteinuria
70 (43,118) 41(14,149) 0.019
Number of significant UPCR
4 0 24(96%)
Number of non significant UPCR
4 8(100%) 1(4%)
1Day of onset of proteinuria: Occurrence of proteinuria on the time scale “...-3, -2, -1, 0, +1, +2, +3,” wherein “0” corresponds to the day of defervescence.
2Day of peak proteinuria: Occurrence of maximum proteinuria on the time scale “...-3, -2, -1, 0, +1, +2 +3,” wherein “0” corresponds to the day of defervescence.
3Day of nadir platelet count: Occurrence of lowest platelet level on the time scale “...-3, -2, -1, 0, +1, +2, +3,....” wherein “0” corresponds to the day of
defervescence.
4 X
2 = 28.2, p < 0.005.
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